The word “randomized” is incomplete without knowing what participants were randomized to receive. This pilot compared two active doses rather than active treatment with placebo. Primary report
Study snapshot
Twelve healthy adults received liposomal glutathione for four weeks. Several glutathione measurements and laboratory immune-function markers increased relative to baseline. The small study did not detect overall differences between the dose groups. The manufacturer supplied funding and the tested product, with its role disclosed in the report. Primary report
Our appraisal: distinguish two causal questions
Random allocation between active doses can help compare those doses. It does not supply an untreated counterfactual for the change shared by both groups. Baseline-to-follow-up changes may contain natural variation, concurrent behavior changes, or measurement effects.
A lack of a detected dose difference should also not be translated into equal effectiveness. With very small groups, the estimates may be too imprecise to resolve a meaningful difference.
The laboratory endpoints need equally careful framing. A change in a cell-based assay is not evidence that participants experienced fewer infections or improved recovery from illness. Dramatic percentage changes can be particularly misleading when the initial value, variability, and clinical relationship are unclear.
This pilot can motivate a more rigorous controlled study and help identify measurable outcomes. It cannot establish broad disease-prevention claims or validate every product labeled liposomal. Review should examine individual trajectories, assay reproducibility, multiplicity, missing data, and whether outcome selection was prespecified. Funding should remain transparent without being treated as either automatic disqualification or a reason to accept the conclusions uncritically.
Frequently asked questions
Was there a placebo group?
No. The pilot compared active dose groups.
How large was the study?
It included 12 healthy adults.
Were clinical infection outcomes the main evidence?
No. The reported findings concerned laboratory measurements.
Does random dose allocation remove every source of bias?
No. It answers only the contrast actually randomized.
Does no dose difference establish equivalence?
No. Limited precision is important here.
Can the results validate all liposomal formulations?
No. Formulation identity matters.
What would strengthen the evidence?
An adequately sized controlled design with prespecified outcomes and clinically relevant follow-up.